Analyst Update: Five Below, Myriad Genetics, Charles Schwab

Analysts adjusted their ratings on Five Below Inc (FIVE), Myriad Genetics, Inc. (MYGN), and Charles Schwab Corp (SCHW)

Mar 26, 2015 at 11:30 AM
facebook twitter linkedin


Analysts are weighing in today on retailer Five Below Inc (NASDAQ:FIVE), molecular diagnostics firm Myriad Genetics, Inc. (NASDAQ:MYGN), and savings-and-loan issue Charles Schwab Corp (NYSE:SCHW). Here's a quick look at today's brokerage notes on FIVE, MYGN, and SCHW.

  • Following last night's fourth-quarter earnings beat, the shares of FIVE are up nearly 11% to reach $35.75, reducing their year-to-date deficit to 12.4%. In response, no fewer than five brokerage firms revised their price targets on the equity, with the loftiest hike coming from Dougherty & Company, which raised its price target by $4 to $40. Meanwhile, Deutsche Bank Securities upped its target by $1 to $40, underscored a "buy" rating, and waxed optimistic on FIVE's new management team and long-term store growth potential. The largest cut came from Credit Suisse, which lowered its price target by $7 to $38. Looking back, the shares of Five Below Inc have been in recovery mode, up 25.4% from their March 10 two-year low of $28.51. Accordingly, calls have been popular in the options pits, as FIVE's 50-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) call/put volume ratio of 4.92 ranks higher than 90% of all equivalent readings taken over the past year. Meanwhile, approximately 18.7% of the stock's available float is sold short, which would take nearly seven sessions to buy back, at average trading volumes.

  • MYGN is following sector peer EXACT Sciences Corporation (NASDAQ:EXAS) lower this morning, after Goldman Sachs cut its rating to "sell" from "neutral" while lowering its price target by $6 to $25 -- in annual-low territory. At last check, the shares of Myriad Genetics, Inc. were down 3.1% to hit $35.06, reducing their year-to-date lead to 2.9%. Short sellers have taken a shine to MYGN, as roughly 45.7% of the stock's available float is sold short. What's more, it would take these speculators over 54 sessions to cover their bets, at the stock's average pace of trading.

  • Barclays upgraded SCHW to "overweight" from "underweight" while raising its price target by $9 to $34 -- in terrain not charted in more than a decade -- sending the shares up 1.7% to reach $29.70. On the charts, Charles Schwab Corp has been trending upwards, with the shares gaining 27.2% since notching an annual low of $23.35 on Oct. 15. Additionally, the stock is presently spitting distance from its 14-year high of $31.73, tagged earlier this month. A good portion of the brokerage bunch is bearish on SCHW, though, as 62% of covering analysts rate the stock a "hold" or worse. Furthermore, the stock's average 12-month price target of $32.18 represents just an 8.4% premium to current trading levels. More upbeat analyst attention could propel SCHW even higher.

 

Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

 
Best stocks for October and worst stocks for October
 


 


 
Special Offers from Schaeffer's Trading Partners